Stem cell transplant for advanced dry age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests if transplanting lab-grown retinal cells (RPE cells) into the eye can help people with late-stage dry AMD. It aims to slow vision loss and possibly improve sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 to 80 years old
- You have the dry form of AMD with a large area of damage (bigger than a pinhead) in the center of your macula, or you had wet AMD that has now become stable with scar tissue
- Vision in the study eye is very low – you can read between 5 and 34 letters on an eye chart (roughly 20/800 to 20/2000 vision)
- If both eyes are eligible, the worse-seeing eye will be used (or the right eye if they are equal)
- You have not had any eye surgery, laser, or anti-VEGF injections in the study eye in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if repeated low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a condition that causes gradual vision loss. The therapy uses red light to potentially slow or improve vision problems.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests if using your own stem cells to create retinal cells can help treat advanced age-related macular degeneration (AMD). If you have severe vision loss from AMD, this approach may restore some sight.
Hear when a new AMD - Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.